Kianoosh Kaveh, DO
Nephrology · Port Charlotte, FLNPI 1174524219
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,323 of the $4,097 with a category attached, or 81.1%. It is spread thinly across 27 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,645 and has fallen 60.6% since, to $647 in 2025.
Across 93 payments — averaging $44.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$813
- Astrazeneca UK Limited$638
- AstraZeneca$503
- Mallinckrodt Hospital Products Inc.$338
- Akebia Therapeutics Inc$190
- Calliditas Therapeutics US Inc.$172
- plus $1K from 21 others
Across 111 payments — averaging $10,495 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$415K
- Eli Lilly$386K
- GSK$191K
- Gilead$65K
- Kadmon Corporation LLC$52K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$22K
- plus $33K from 4 others
What the payments were for
- Travel & lodging$76019%
- Food & beverage$3,32381%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,097 in reported general payments places this provider in the 75th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 230 | $289,867 |
| JynarqueTolvaptan | 11 | $218,729 |
| AuryxiaFerric Citrate | 33 | $67,269 |
| LokelmaSodium Zirconium Cyclosilicate | 49 | $66,274 |
| VelphoroSucroferric Oxyhydroxide | 21 | $64,683 |
| JardianceEmpagliflozin | 49 | $46,852 |
| VeltassaPatiromer Calcium Sorbitex | 21 | $28,397 |
| Lanthanum Carbonate | 17 | $24,148 |
| Sevelamer Carbonate | 78 | $17,278 |
| Cinacalcet Hcl | 14 | $7,296 |
| DapagliflozinDapagliflozin Propanediol | 11 | $6,488 |
| Bumetanide | 75 | $3,244 |
| Potassium Citrate ErPotassium Citrate | 24 | $3,167 |
| Losartan Potassium | 320 | $2,811 |
| Allopurinol | 253 | $1,918 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $503 | $356,141279 claims |
| Otsuka America Pharmaceutical, Inc.Jynarque | $73 | $218,72911 claims |
| Akebia Therapeutics IncAuryxia | $190 | $67,26933 claims |
| Fresenius USA Marketing, Inc.Velphoro | $59 | $64,68321 claims |
| Boehringer IngelheimJardiance | $27 | $46,85249 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 756 nephrology providers in Florida.
Other nephrology in Port Charlotte
- Rohit PankhaniyaPort Charlotte$34K
- Arvind MadanOrlando$943K
- John CopleyWeston$934K
- Jorge LarranagaKissimmee$825K
- Carlos BejarFort Lauderdale$530K
- Wayne KotzkerFort Lauderdale$472K
- Jason RothschildTemple Terrace$413K
- Daniel PatelDaytona Beach$227K
- Rafael Baez BonillaFort Lauderdale$175K
- Gabriel ContrerasMiami$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.